Sibrotuzumab, a humanized monoclonal anti-FAP antibody, enhanced cytotoxic activity against FAP-expressing tumor cells in in vitro experiments, but had no therapeutic effect observed in clinical studies (89–92). Here, FAP is linked to neoplasm.